Stockholm, January 16, 2025 - Intervacc AB (publ) has received orders from Dechra Pharmaceuticals with a total order value equivalent to approximately SEK 5.8 million. Orders received relate to Strangvac®, a ... Read more
The shareholders of Intervacc AB (publ), reg. no. 556238-1748 (the “Company”), are hereby invited to the Extraordinary General Meeting (“EGM”) to be held on Friday 31 January 2025 at 3.00 p.m. at Cirio Advokatbyrå, ... Read more
NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, ... Read more
Stockholm, December 6, 2024 – Intervacc AB (publ) announces that Strangvac®, a vaccine against equine strangles, is now back in stock for delivery in all European markets where the vaccine has been ... Read more
